R Judd Jessup Sells 7,076 Shares of CorVel (NASDAQ:CRVL) Stock

CorVel Corp. (NASDAQ:CRVL) Director R Judd Jessup sold 7,076 shares of the firm’s stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $76.94, for a total transaction of $544,427.44. Following the sale, the director owned 115,045 shares of the company’s stock, valued at approximately $8,851,562.30. The trade was a 5.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

R Judd Jessup also recently made the following trade(s):

• On Monday, November 10th, R Judd Jessup sold 210 shares of CorVel stock. The stock was sold at an average price of $76.27, for a total transaction of $16,016.70.

CorVel Stock Performance

Shares of CRVL traded down $0.32 during mid-day trading on Wednesday, hitting $77.23. 266,114 shares of the company’s stock were exchanged, compared to its average volume of 146,183. The company has a market cap of $3.96 billion, a price-to-earnings ratio of 39.81 and a beta of 0.98. CorVel Corp. has a fifty-two week low of $70.47 and a fifty-two week high of $128.61. The stock’s 50-day moving average is $77.54 and its 200-day moving average is $92.48.

CorVel (NASDAQ:CRVL) last announced its quarterly earnings data on Tuesday, November 4th. The business services provider reported $0.54 earnings per share (EPS) for the quarter. CorVel had a return on equity of 32.31% and a net margin of 10.98%.The business had revenue of $239.64 million for the quarter.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of CorVel in a research note on Tuesday, October 14th. Wall Street Zen downgraded CorVel from a “buy” rating to a “hold” rating in a report on Saturday. One analyst has rated the stock with a Hold rating, According to MarketBeat.com, the company has an average rating of “Hold”.

Hedge Funds Weigh In On CorVel

A number of hedge funds and other institutional investors have recently bought and sold shares of CRVL. Xponance Inc. raised its holdings in shares of CorVel by 4.9% during the first quarter. Xponance Inc. now owns 2,008 shares of the business services provider’s stock valued at $225,000 after buying an additional 94 shares during the last quarter. Ballentine Partners LLC boosted its holdings in shares of CorVel by 4.2% in the first quarter. Ballentine Partners LLC now owns 2,531 shares of the business services provider’s stock worth $283,000 after buying an additional 102 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of CorVel by 0.7% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,961 shares of the business services provider’s stock valued at $1,640,000 after buying an additional 115 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of CorVel by 0.9% during the second quarter. The Manufacturers Life Insurance Company now owns 15,918 shares of the business services provider’s stock worth $1,636,000 after acquiring an additional 139 shares in the last quarter. Finally, Arizona State Retirement System lifted its stake in shares of CorVel by 1.7% in the 3rd quarter. Arizona State Retirement System now owns 9,113 shares of the business services provider’s stock valued at $706,000 after purchasing an additional 155 shares during the last quarter. 51.36% of the stock is currently owned by institutional investors and hedge funds.

About CorVel

CorVel Corporation provides workers’ compensation, auto, liability, and health solutions. It applies technology, including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. The company also offers network solutions services, including automated medical fee auditing, preferred provider management and reimbursement, retrospective utilization review, facility claim review, professional review, pharmacy, directed care, clearinghouse, independent medical examination, and inpatient medical bill review services, as well as Medicare solutions.